

9 May 2024

## Mernova's Strong Progress Continues

### Highlights:

- **Additional product launches across various provinces in addition to those previously announced**
- **Agreement with Best Kind Edibles signed for manufacturing of cannabis edibles as an extension to existing product suite**
- **Q2 confirmed purchase orders of \$1.3m to date, highlighting ongoing strength of Ritual brand at the midpoint of the quarter**
- **Purchase orders follow unaudited Q1 revenues of \$1.75m and FY23 full year revenues of \$6.9m**

**Melodiol Global Health Limited (ASX:ME1) ('Melodiol' or 'the Company')** is pleased to advise that its wholly owned Canadian subsidiary, Mernova, continues to make strong operational progress. In recent weeks, Mernova has achieved further new product launches, in addition to those announced on 2 April 2024. These include:

- Manitoba
  - Two new products listed, Sacred Sage 3.5g and Sacred Sage 3x0.5g
- Nova Scotia Liquor Commission
  - French Cookies 12x0.5g pre rolls one time offer approved
- Ontario Cannabis Store
  - Black Mamba 12x0.5g pre-rolls now approved
- New Brunswick
  - Black Mamba / French Cookies / Halifax Sage combo pack approved
- Newfoundland
  - 9 SKUs pending for June launch
- Prince Edward Island, Limited Edition Program for the following products
  - French cookies 3.5g
  - Halifax Sage 3.5g
  - Black Mamba 3.5g
  - Black Mamba / French Cookies / Halifax Sage combo pack
  - Black Mamba / Sugar Bumb Punch pre rolls combo pack
- Yukon Liquor Commission approved 6 new SKUs for launch in May 2024
  - Grape Cream Cake pre rolls 3x0.5g, 7x0.5g, 10x0.5g and 12x0.5g formats
  - Sugar Bomb Punch Vape 1.0g
  - Black Mamba Bubble Has Infused Blunt 1x1.0g

These results indicate the demand for the Ritual brand's growing suite of products and strains. As an update to the 2 April 2024 announcement, Mernova has now signed a supply agreement with Best Kind Edibles for

manufacturing of cannabis edibles (2x5mg) which will launch in the fall of 2024. During Q2 to date, Mernova has received purchase orders for \$1.3m (C\$1.2m at current C\$ to A\$ of 1.11) of product. This strong start to the quarter follows unaudited Q1 revenues of \$1.75m, and FY23 revenues of \$6.9m.

**Management commentary:**

**CEO and Managing Director, Mr William Lay said:** *"Mernova continues to deliver strong revenue figures and we are very proud of the team for their ongoing commitment to high quality cannabis. We look forward to generating further purchase orders as new products and formats become available."*

**-Ends-**

**Authority and Contact Details**

This announcement has been authorised for release by the CEO and MD of Melodiol Global Health Limited.

For further information, please contact:

**Investor Enquiries**

Melodiol Global Health Limited

E: [info@cresopharma.com](mailto:info@cresopharma.com)

P: +61 (0) 497 571 532

**About Melodiol**

Melodiol Global Health Limited (ASX:ME1) brings the best of cannabis and other plant-based products to better the lives of people and animals. Melodiol strives for the highest quality in its products. It develops cannabis, hemp-derived and other plant based therapeutic, nutraceutical, and lifestyle products with wide consumer reach.

To learn more please visit: <https://melodiolglobalhealth.com/>

**Melodiol offices:**

**Australia:** Suite 5 CPC, 145 Stirling Hwy, Nedlands, WA, 6009

**Canada:** 59 Payzant Drive, Windsor, Nova Scotia, B0N 2T0 and 50 Ivey Ln, Windsor, Nova Scotia, B0N 2T0

**Forward Looking statements**

This announcement contains forward-looking statements with respect to Melodiol and its respective operations, strategy, investments, financial performance and condition.

These statements generally can be identified by use of forward-looking words such as "may", "will", "expect", "estimate", "anticipate", "intends", "believe" or "continue" or the negative thereof or similar variations. The actual results and performance of Melodiol could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition and government regulation.

The cautionary statements qualify all forward-looking statements attributable to Melodiol and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of

this announcement and Melodiol has no obligation to up-date such statements, except to the extent required by applicable laws.